New insights into the prevention and treatment of familial breast cancer

Research output: Contribution to journalArticle

Abstract

Individuals who inherit a deleterious mutation in BRCA1 or BRCA2 are at very high risk for breast cancer but there are several strategies available for successfully managing this risk. Breast cancers that develop in the context of germline BRCA gene mutation present challenges for management but also opportunities. DNA damaging agents, like cisplatin, and the new class of drugs called PARP inhibitors exploit the underlying defect in DNA damage repair to great effect.

Original languageEnglish (US)
Pages (from-to)294-298
Number of pages5
JournalJournal of Surgical Oncology
Volume103
Issue number4
DOIs
StatePublished - Mar 15 2011
Externally publishedYes

Fingerprint

Breast Neoplasms
Mutation
DNA Repair
Cisplatin
DNA Damage
DNA
Pharmaceutical Preparations
Genes
Familial Breast Cancer
Poly(ADP-ribose) Polymerase Inhibitors

Keywords

  • BRCA1
  • BRCA2
  • Chemoprevention
  • Cisplatin
  • Mastectomy
  • Oophorectomy
  • PARP inhibitors

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

New insights into the prevention and treatment of familial breast cancer. / Euhus, David M.

In: Journal of Surgical Oncology, Vol. 103, No. 4, 15.03.2011, p. 294-298.

Research output: Contribution to journalArticle

@article{fa9a2565d242446cb415f8e2bbf52a4e,
title = "New insights into the prevention and treatment of familial breast cancer",
abstract = "Individuals who inherit a deleterious mutation in BRCA1 or BRCA2 are at very high risk for breast cancer but there are several strategies available for successfully managing this risk. Breast cancers that develop in the context of germline BRCA gene mutation present challenges for management but also opportunities. DNA damaging agents, like cisplatin, and the new class of drugs called PARP inhibitors exploit the underlying defect in DNA damage repair to great effect.",
keywords = "BRCA1, BRCA2, Chemoprevention, Cisplatin, Mastectomy, Oophorectomy, PARP inhibitors",
author = "Euhus, {David M}",
year = "2011",
month = "3",
day = "15",
doi = "10.1002/jso.21664",
language = "English (US)",
volume = "103",
pages = "294--298",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - New insights into the prevention and treatment of familial breast cancer

AU - Euhus, David M

PY - 2011/3/15

Y1 - 2011/3/15

N2 - Individuals who inherit a deleterious mutation in BRCA1 or BRCA2 are at very high risk for breast cancer but there are several strategies available for successfully managing this risk. Breast cancers that develop in the context of germline BRCA gene mutation present challenges for management but also opportunities. DNA damaging agents, like cisplatin, and the new class of drugs called PARP inhibitors exploit the underlying defect in DNA damage repair to great effect.

AB - Individuals who inherit a deleterious mutation in BRCA1 or BRCA2 are at very high risk for breast cancer but there are several strategies available for successfully managing this risk. Breast cancers that develop in the context of germline BRCA gene mutation present challenges for management but also opportunities. DNA damaging agents, like cisplatin, and the new class of drugs called PARP inhibitors exploit the underlying defect in DNA damage repair to great effect.

KW - BRCA1

KW - BRCA2

KW - Chemoprevention

KW - Cisplatin

KW - Mastectomy

KW - Oophorectomy

KW - PARP inhibitors

UR - http://www.scopus.com/inward/record.url?scp=79952024775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952024775&partnerID=8YFLogxK

U2 - 10.1002/jso.21664

DO - 10.1002/jso.21664

M3 - Article

VL - 103

SP - 294

EP - 298

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -